Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital.

Launched by JINNAH POSTGRADUATE MEDICAL CENTRE · Jun 4, 2023

Keywords

ClinConnect Summary

Plaque psoriasis is a chronic autoimmune skin disorder characterized by the formation of thick, scaly plaques on the skin surface. It affects millions of individuals worldwide and significantly impacts their quality of life. While several treatment options exist, a substantial number of patients with moderate to severe plaque psoriasis fail to achieve satisfactory results or experience intolerable side effects with conventional therapies.

Psoriasis is pathogenically driven by proinflammatory cytokines and mediated by T cells and dendritic cells. In recent years, the advent of biologic agen...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Known plaque psoriasis
• • Either gender
• • Age 30-80 years.
• Exclusion Criteria:
• • Patients with history of eczema.
• • Patients with history connective tissue disorder, vasculitis malignancy, seropositive or seronegative arthritis.
• • Patients with history of malignancy.
• • Patient with history of hepatis B, C or AIDS.
• • Immunocompromised patients.
• • Pregnant patients assessed by history and confirmed by dating scan.
• • Patients with history of chronic liver disease, chronic kidney disease, asthma, acute coronary syndrome, congestive heart failure and chronic obstructive pulmonary disease will be excluded.